Clinical Trials

C3651003

C3651003: Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

C3651003: Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

 

Clinical trial for people that have unexplained weight loss associated with non-small cell lung cancer, pancreatic cancer or colorectal cancer, and no other reason for weight loss. This study will help us learn if an investigational or study drug can treat symptoms related to unexplained weight loss in people with these cancers compared to a placebo.

Principal Investigator

Aaron H. Chevinsky, MD

Contact

Riverside Cancer Clinical Team
757-534-6890
[email protected]

Locations

All Peninsula Cancer Institute and Cancer Specialists of Tidewater sites

Status

Recruiting

Category

Oncology

Study #

NCT05546476